Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?

被引：6
|
作者：
Fiorelli, Alfonso [1 ]
Vitiello, Fabiana [2 ]
Morgillo, Floriana [3 ]
Santagata, Mario [4 ]
Spuntarelli, Chiara [4 ]
Di Domenico, Marina [5 ]
Santini, Mario [1 ]
Bianco, Andrea [6 ]
机构：
[1] Univ Campania Luigi Vanvitelli, Thorac Surg Unity, Dept Translat Med Sci, Naples, Italy
[2] Hosp Vincenzo Monaldi, Dept Pneumol & Oncol, Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Oncol Unit, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Maxillo & Orofacial Unit, Naples, Italy
[5] Univ Campania Luigi Vanvitelli, Gen Pathol Unit, Naples, Italy
[6] Univ Campania Luigi Vanvitelli, Pneumol Unity, Dept Translat Med Sci, Naples, Italy
来源：
TRANSLATIONAL CANCER RESEARCH | 2019年 / 8卷
关键词：
D O I：
10.21037/tcr.2019.06.28
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S618 / S620
页数：3
相关论文
共 50 条
  • [21] RBM17 Expression Is Associated With the Efficacy of ICI Monotherapy in NSCLC With Low PD-L1 Expression
    Nagamine, Hiroaki
    Yashiro, Masakazu
    Yoshimoto, Naoki
    Izumi, Motohiro
    Sugimoto, Akira
    Nakahama, Kenji
    Ogawa, Koichi
    Matsumoto, Yoshiya
    Sawa, Kenji
    Tani, Yoko
    Kaneda, Hiroyasu
    Mitsuoka, Shigeki
    Yamada, Kazuhiro
    Watanabe, Tetsuya
    Aasai, Kazuhisa
    Fukumura, Kazuhiro
    Mayeda, Akila
    Kawaguchi, Tomoya
    ANTICANCER RESEARCH, 2023, 43 (10) : 4663 - 4672
  • [22] PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
    Di Federico, Alessandro
    De Giglio, Andrea
    Parisi, Claudia
    Gelsomino, Francesco
    Ardizzoni, Andrea
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 160
  • [23] PD-L1 expression in NSCLC
    Janzic, U.
    Kern, I.
    Janzic, A.
    Cavka, L.
    Cufer, T.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S58 - S59
  • [24] PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
    Liu, S. -Y. M.
    Deng, J. -Y.
    Yan, H-H.
    Yang, M. -Y.
    Xu, C. -R.
    Zheng, M. -Y.
    Gan, B.
    Zhang, X. -C.
    Tu, H-Y.
    Yang, J. -J.
    Chen, H. -J.
    Wang, B. -C.
    Li, Y.
    Zhou, Q.
    Wu, Y. -L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S319 - S320
  • [25] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
    Liu, Qiao
    Zhou, Zhen
    Luo, Xia
    Yi, Lidan
    Peng, Liubao
    Wan, Xiaomin
    Tan, Chongqing
    Zeng, Xiaohui
    FRONTIERS IN PHARMACOLOGY, 2022, 12
  • [26] The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors
    Schakenraad, Alexandra
    Hashemi, Sayed
    Twisk, Jos
    Houda, Ilias
    Ulas, Ezgi
    Daniels, Johannes M. A.
    Veltman, Joris
    Bahce, I.
    LUNG CANCER, 2021, 162 : 36 - 41
  • [27] Real-World Prognostic Model of Overall Survival in Patients With Advanced NSCLC Receiving Anti-PD1/PD-L1 as 2L Monotherapy
    Julian, C.
    Machado, R.
    Girish, S.
    Chanu, P.
    Heinzmann, D.
    Harbron, C.
    Gershon, A.
    Pfeiffer, S.
    Zou, W.
    Quarmby, V.
    Zhang, Q.
    Chen, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S644 - S644
  • [28] Real-world evaluation of pembrolizumab monotherapy for PD-L1 positive (TPS>50%) metastatic NSCLC in France
    Perol, M.
    Filleron, T.
    Quantin, X.
    Chouaid, C.
    Valette, C. Audigier
    Lena, H.
    Kaderbhai, C.
    Fabre, C.
    Santorelli, M.
    Bensimon, L.
    Burke, T.
    Couch, D.
    Nguyen, E.
    Courtinard, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S757 - S758
  • [29] Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data
    Velcheti, Vamsidhar
    Hu, Xiaohan
    Li, Yeran
    El-Osta, Hazem
    Pietanza, M. Catherine
    Burke, Thomas
    CANCERS, 2022, 14 (04)
  • [30] Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
    Pan, Yingying
    Liu, Xinyu
    Zhang, Wei
    Wang, Wanying
    Wang, Haowei
    Luo, Libo
    Jia, Keyi
    Shao, Chuchu
    Mao, Shiqi
    Qiu, Tianyu
    Ni, Jun
    Yu, Jia
    Wang, Lei
    Chen, Bin
    Xiong, Anwen
    Gao, Guanghui
    Chen, Xiaoxia
    Wu, Fengying
    Zhou, Caicun
    Wu, Chunyan
    Ren, Shengxiang
    LUNG CANCER, 2023, 181
12345